EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

被引：3
|
作者：
Le, Xiuning [1 ]
Nadler, Eric [2 ]
Costa, Daniel B. [3 ]
Heymach, John Victor [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Baylor Univ, Med Ctr, Dallas, TX USA
[3] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA USA
来源：
TARGETED ONCOLOGY | 2023年 / 18卷 / 06期
关键词：
AFATINIB; OSIMERTINIB; NSCLC;
D O I：
10.1007/s11523-023-00994-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[media not available: see fulltext]
引用
收藏
页码：807 / 817
页数：11
相关论文
共 50 条
  • [31] Sequential treatment in advanced non-small cell lung cancer harboring EGFR mutations
    Hsu, Ping-Chih
    Chang, John Wen-Cheng
    Chang, Ching-Fu
    Huang, Chen-Yang
    Yang, Cheng-Ta
    Kuo, Chih-Hsi Scott
    Fang, Yueh-Fu
    Wu, Chiao-En
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2022, 16
  • [32] Sequential treatment in advanced non-small cell lung cancer harboring EGFR mutations
    Hsu, Ping-Chih
    Chang, John Wen-Cheng
    Chang, Ching-Fu
    Huang, Chen-Yang
    Yang, Cheng-Ta
    Kuo, Chih-Hsi Scott
    Fang, Yueh-Fu
    Wu, Chiao-En
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2022, 16
  • [33] Uncommon EGFR mutations in advanced non-small cell lung cancer
    O'Kane, Grainne M.
    Bradbury, Penelope A.
    Feld, Ronald
    Leighl, Natasha B.
    Liu, Geoffrey
    Pisters, Katherine -M.
    Kamel-Reid, Suzanne
    Tsao, Ming S.
    Shepherd, Frances A.
    LUNG CANCER, 2017, 109 : 137 - 144
  • [34] EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China
    Xu, Jianlin
    Jin, Bo
    Chu, Tianqing
    Dong, Xue
    Yang, Haitang
    Zhang, Yanwei
    Wu, Dan
    Lou, Yuqing
    Zhang, Xueyan
    Wang, Huiming
    Han, Baohui
    LUNG CANCER, 2016, 96 : 87 - 92
  • [35] Drug Resistance to EGFR Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer
    Shien, Kazuhiko
    Yamamoto, Hiromasa
    Soh, Junichi
    Miyoshi, Shinichiro
    Toyooka, Shinichi
    ACTA MEDICA OKAYAMA, 2014, 68 (04) : 191 - 200
  • [36] Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations
    Shi, Chen
    Zhang, Cong
    Fu, Zhiwen
    Liu, Jinmei
    Zhou, Yuanfeng
    Cheng, Bao
    Wang, Cong
    Li, Shijun
    Zhang, Yu
    ACTA PHARMACEUTICA SINICA B, 2023, 13 (06) : 2613 - 2627
  • [37] Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations
    Chen Shi
    Cong Zhang
    Zhiwen Fu
    Jinmei Liu
    Yuanfeng Zhou
    Bao Cheng
    Cong Wang
    Shijun Li
    Yu Zhang
    Acta Pharmaceutica Sinica B, 2023, (06) : 2613 - 2627
  • [38] Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence
    Wang, Xiaochun
    Goldstein, David
    Crowe, Philip J.
    Yang, Jia-Lin
    ONCOTARGETS AND THERAPY, 2016, 9 : 5461 - 5473
  • [39] Developing of EGFR resistant mutations to Tyrosine Kinase Inhibitors (TKI) in Non-Small Cell Lung Cancer (NSCLC)
    Raez, L. E.
    Baca, Y.
    Nagasaka, M.
    Nieva, J.
    Mandani, H.
    Wanderwalde, A.
    Borghaei, H.
    Naban, C.
    Langer, C.
    Socinsky, M. A.
    Lopes, G.
    Khan, H.
    Wozniak, A.
    Carracedo, C.
    Liu, S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S597 - S597
  • [40] Effectiveness Of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors On Non-Small Cell Lung Cancer Harboring Rare EGFR Mutations
    Chang, L. -C.
    Chen, K. -Y.
    Shih, J. -Y.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
12345